icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
Exposure-Response Analyses for Efficacy (SVR12) for the Direct Acting Antiviral Regimen of Paritaprevir/r, Ombitasvir with Dasabuvir ± Ribavirin in Subjects with HCV Genotype 1 Infection
 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Amit Khatri*1, Sven Mensing2, Thomas Podsadecki3, Walid Awni1, Rajeev Menon1, Sandeep Dutta1 1Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, United States; 2Clinical Pharmacology and Pharmacometrics, AbbVie, Ludwigshafen, Germany; 3Infectious Disease, GPRD, AbbVie, North Chicago, United States

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif